| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Ono Pharmaceutical Co. Ltd (PINK: OPHLF)
OPHLF Technical Analysis
5
| As on 2nd Apr 2025 OPHLF STOCK Price closed @ 9.40 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 24.96 & Strong Sell for SHORT-TERM with Stoploss of 23.27 we also expect STOCK to react on Following IMPORTANT LEVELS. |
OPHLFSTOCK Price
| Open | 9.40 | Change | Price | % |
| High | 9.40 | 1 Day | 0.00 | 0.00 |
| Low | 9.40 | 1 Week | -3.98 | -29.75 |
| Close | 9.40 | 1 Month | -4.52 | -32.47 |
| Volume | 39010 | 1 Year | -11.60 | -55.24 |
| 52 Week High 27.76 | 52 Week Low 11.64 | ||||
PINK USA Most Active Stocks
| HMBL | 0.00 | % |
| MDCE | 0.00 | % |
| AFFU | 0.00 | % |
| AITX | 0.00 | % |
| RDAR | 0.00 | % |
| PSWW | 0.00 | % |
| TXGE | 3316.21 | 2.69% |
| TMSH | 0.00 | % |
| TWOH | 0.00 | % |
| DPLS | 0.00 | % |
PINK USA Top Gainers Stocks
PINK USA Top Losers Stocks
| OPHLF Daily Charts |
OPHLF Intraday Charts |
Whats New @ Bazaartrend |
OPHLF Free Analysis |
|
|
OPHLF Important Levels Intraday
| RESISTANCE | 9.40 |
| RESISTANCE | 9.40 |
| RESISTANCE | 9.40 |
| RESISTANCE | 9.40 |
| RESISTANCE | 9.40 |
| RESISTANCE | 9.40 |
| RESISTANCE | 9.40 |
| RESISTANCE | 9.40 |
OPHLF Forecast June 2025
| 4th UP Forecast | 10.85 |
| 3rd UP Forecast | 10.38 |
| 2nd UP Forecast | 10.1 |
| 1st UP Forecast | 9.81 |
| 1st DOWN Forecast | 8.99 |
| 2nd DOWN Forecast | 8.7 |
| 3rd DOWN Forecast | 8.42 |
| 4th DOWN Forecast | 7.95 |
OPHLF Weekly Forecast
| 4th UP Forecast | 9.40 |
| 3rd UP Forecast | 9.40 |
| 2nd UP Forecast | 9.40 |
| 1st UP Forecast | 9.40 |
| 1st DOWN Forecast | 9.40 |
| 2nd DOWN Forecast | 9.40 |
| 3rd DOWN Forecast | 9.40 |
| 4th DOWN Forecast | 9.40 |
OPHLF Forecast2025
| 4th UP Forecast | 44.78 |
| 3rd UP Forecast | 33.43 |
| 2nd UP Forecast | 26.42 |
| 1st UP Forecast | 19.41 |
| 1st DOWN Forecast | -0.61 |
| 2nd DOWN Forecast | -7.62 |
| 3rd DOWN Forecast | -14.63 |
| 4th DOWN Forecast | -25.98 |
Ono Pharmaceutical Co. Ltd ( PINK USA Symbol : OPHLF )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
OPHLF Business Profile
Ono Pharmaceutical Co., Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. The company offers OPDIVO intravenous infusions for the treatment of malignant tumors; KYPROLIS for intravenous injection; EMEND capsules/PROEMEND intravenous injections for chemotherapy-induced nausea and vomiting; DEMSER Capsule for improvement of the symptoms in patients with pheochromocytoma; and BRAFTOVI capsules, and MEKTOVI and VELEXBRU tablets for malignant tumors. It also provides GLACTIV and FORXIGA tablets for type 2 diabetes; ORENCIA injections for rheumatoid arthritis; RIVASTACH patches for Alzheimer's disease; PARSABIV, an intravenous injection for dialysis patients; ONOACT injections for tachyarrhythmia; STAYBLA tablets for overactive bladder; OPALMON tablets to treat peripheral circulatory disorder; ONON capsules and dry syrups for bronchial asthma and allergic rhinitis; CORALAN for treatment of chronic heart failure; and RECALBON tablets for osteoporosis. In addition, the company is developing products for colorectal, esophageal, gastric or esophago-gastric junction, small and non-small cell lung, ovarian, pancreatic, prostate, biliary tract, hematologic, and head and neck cancers; hepatocellular, urothelial, and virus positive/negative solid carcinoma; glioblastoma; multiple myeloma; malignant pleural mesothelioma; solid tumors; central nervous system, primary testicular, and lymphoplasmacytic; acute myeloid leukemia; melanoma; primary macroglobulinemia; chronic heart failure; Parkinson's disease; structural damage of the joints in rheumatoid arthritis; polymyositis/dermatomyositis; osteoarthritis; enthesopathy; pemphigus; celebral infarction; acromegaly; thrombosis; and autoimmune disease. The company has research and collaboration agreement with Numab Therapeutics AG and Caris Life Sciences, Inc. Ono Pharmaceutical Co., Ltd. was founded in 1717 and is headquartered in Osaka, Japan. Address: 8-2, Kyutaromachi 1-chome, Osaka, Japan, 541-8564
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service